Differential signature of fecal microRNAs in patients with pancreatic cancer

49Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

The potential value of microRNAs as new biomarkers for pancreatic cancer (PCa) screening was explored in this study. Fecal microRNAs from stool samples obtained from 29 PCa patients, 22 chronic pancreatitis (CP) patients and 13 normal individuals were extracted, and 7 microRNAs (miR-16, miR-21, miR-155, miR-181a, miR-181b, miR-196a and miR-210) were detected. miR-181b and miR-210 discriminated PCa from normal individuals with receiver operating characteristic (ROC) curves and area under curve (AUC-ROC) of 0.745 and 0.772, respectively. There was a significant correlation between miR-196a and the maximum tumor diameter (Spearman r=0.516, P=0.041). These findings suggest that fecal microRNAs such as miR-181b and miR-210 may have potential to be used as new biomarkers for PCa screening.

Cite

CITATION STYLE

APA

Ren, Y., Gao, J., Liu, J. Q., Wang, X. W., Gu, J. J., Huang, H. J., … Li, Z. S. (2012). Differential signature of fecal microRNAs in patients with pancreatic cancer. Molecular Medicine Reports, 6(1), 201–209. https://doi.org/10.3892/mmr.2012.862

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free